1. Schutzm, F. A., Je, Y., Richards, C. J., & Choueiri, T. K. (2012). Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. Journal of Clinical Oncology. Feb 6.
2. EMA. Sunitinib (Sutent®)—Summary of product characteristics: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000687/WC500057737.pdf (accessed on October 2011).
3. Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., et al. (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. The New England Journal of Medicine, 356(2), 115–124. Jan 11.
4. Rini, B. I., Tamaskar, I., Shaheen, P., Salas, R., Garcia, J., Wood, L., et al. (2007). Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. Journal of the National Cancer Institute, 99(1), 81–83. Jan 3.
5. Chen, A., & Agarwal, N. (2009). Reversible posterior leucoencephalopathy syndrome associated with sunitinib. Internal Medicine Journal, 39(5), 341–342.